Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 TrialClin. Cancer Res 2021 Nov 10;[EPub Ahead of Print], MM Regan, OA Jegede, CM Mantia, T Powles, L Werner, RJ Motzer, NM Tannir, CH Lee, Y Tomita, MH Voss, ER Plimack, TK Choueiri, BI Rini, HJ Hammers, B Escudier, L Albiges, S Huo, V Del Tejo, B Stwalley, MB Atkins, DF McDermott
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.